



Vertex Pharmaceuticals (ANZ) Pty Ltd
ABN: 34 160 157 157
Suite 3, Level 3
601 Pacific Highway
St Leonards NSW 2065
Australia
Tel: +61 2 8245 0200
www.vrtx.com

Open Letter to Cystic Fibrosis Community in New Zealand: 16 September 2022

Following the news that Pharmac decided not to prioritise funding of Trikafta[®] (elixacaftor/tezacaftor/ivacaftor and ivacaftor) for New Zealanders with cystic fibrosis (CF) at its September prioritisation meeting, we wanted to assure you that Vertex remains committed to New Zealand's CF Community.

While we understand that Pharmac must make choices within a fixed budget, we are surprised by this decision, particularly given their recent public acknowledgment of the clinical impact that Trikafta would have on CF patients in New Zealand.

We will continue to work tirelessly until we achieve reimbursed access to Trikafta for all eligible New Zealanders. While the next steps are not clearly defined at this time, we will continue to work collaboratively with Pharmac to find a path forward so that those who can benefit from Trikafta have the same access as patients in more than 30 other countries around the world.

We will continue to keep you updated via the team at Cystic Fibrosis New Zealand.

Kind regards

Sabrina Barbic
Senior Country Manager, Australia and New Zealand
Vertex Pharmaceuticals